ArticleFrontiers in medicine2026
Tolerance-guided dose adjustment in sublingual immunotherapy for children with dust mite-induced allergic rhinitis: a 6-month prospective cohort study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sublingual immunotherapy (SLIT) is effective for allergic rhinitis (AR), though its efficacy exhibits inter-individual variability and is dose-dependent. Standardized protocols may not achieve optimal outcomes in all pediatric patients, highlighting the need for individualized dose-adjustment strategies. The nasal allergen challenge (NAC), the gold standard for assessing nasal mucosal reactivity, provides an objective tool to evaluate treatment response and guide dose personalization. Objective: To evaluate the short-term (6-month) efficacy of individualized SLIT dose adjustment in children with dust mite-induced AR, and to assess its effects on upper and lower airway inflammation and lung function. Methods: In this prospective cohort study, 235 children (3-14 years) with dust mite-induced AR were assigned to a standard-dose group (SD, Results: After 6 months, all symptom scores improved significantly in both groups (all Conclusion: In this prospective pediatric cohort, individualized SLIT dose adjustment based on tolerance was associated with better short-term outcomes, reduced nasal mucosal reactivity, and improved lung function. These findings support the feasibility of tolerance-guided dose personalization and warrant confirmation in randomized controlled trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.